Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02563769 · ClinicalTrials.gov registry record · Phase 1
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
A Phase 1 study, sponsored by Temple University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02563769 is a Phase 1 study that has completed, run by Temple University. The registered enrollment target is 10 participants.
The verdict
NCT02563769, a Phase 1 study, has completed, sponsored by Temple University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine if it is safe to use the study drug, clavulanic acid, in combination with cocaine. In this study, subjects will receive intravenous (i.v.) cocaine and the study drug, clavulanic acid. The safety of clavulanic acid is being studied so future studies can be done to find out if this drug is helpful in treating cocaine dependence. Currently, there is no available medication treatment for cocaine dependence.
Interventions
- DRUG Placebo
- DRUG Clavulanic acid
- DRUG Intravenous cocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-10-24 |
| Est. Completion | 2018-05-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02563769
The ClinicalTrials.gov registry entry for NCT02563769 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02563769 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02563769 about?
NCT02563769 is a clinical study titled "Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study". The main purpose of this study is to determine if it is safe to use the study drug, clavulanic acid, in combination with cocaine. In this study, subjects will receive intravenous (i.v.) cocaine and the study drug, clavulanic acid. The safety of clavulanic acid is being studied so future studies can ...
What is the current status of trial NCT02563769?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-10-24. Estimated completion is 2018-05-25.
What interventions are being tested in trial NCT02563769?
The interventions under investigation include: Placebo (DRUG), Clavulanic acid (DRUG), Intravenous cocaine (DRUG).
Who is sponsoring clinical trial NCT02563769?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.